Denali Therapeutics Inc. Common Stock (DNLI)

Price$19.52

Value ScoreD

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-7.67%

Price vs S&P 500 (4W)-0.50%

VGM Score47.07

Market Capitalization$3.10B

All Metrics

Book Value / Share (Quarterly)$5.84

P/TBV (Annual)2.44x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-2.64

Price vs S&P 500 (YTD)10.07%

Net Profit Margin (TTM)-36.53%

EPS (TTM)$-2.97

10-Day Avg Trading Volume1.91M

EPS Excl Extra (TTM)$-2.97

EPS (Annual)$-2.97

ROI (Annual)-50.28%

Net Profit Margin (5Y Avg)-332.00%

Cash / Share (Quarterly)$6.23

ROA (Last FY)-44.77%

EBITD / Share (TTM)$-3.13

ROE (5Y Avg)-32.10%

Operating Margin (TTM)-49.71%

Cash Flow / Share (Annual)$-2.70

P/B Ratio3.35x

P/B Ratio (Quarterly)3.29x

Net Income / Employee (Annual)$-1,019,000

EV / Revenue (TTM)7.97x

Net Interest Coverage (TTM)-167.00x

ROA (TTM)-44.20%

EV / EBITDA (TTM)79.65x

EPS Incl Extra (Annual)$-2.97

Current Ratio (Annual)9.16x

Quick Ratio (Quarterly)8.97x

3-Month Avg Trading Volume1.76M

52-Week Price Return37.27%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$5.61

P/S Ratio (Annual)9.37x

Asset Turnover (Annual)0.29x

52-Week High$23.77

Operating Margin (5Y Avg)-352.15%

EPS Excl Extra (Annual)$-2.97

CapEx CAGR (5Y)25.11%

Tangible BV CAGR (5Y)17.48%

26-Week Price Return0.26%

Quick Ratio (Annual)8.85x

13-Week Price Return-0.91%

Total Debt / Equity (Annual)0.01x

Current Ratio (Quarterly)9.28x

Enterprise Value$2.72B

Asset Turnover (TTM)0.25x

Book Value / Share Growth (5Y)-7.43%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-43.93%

Cash / Share (Annual)$5.56

3-Month Return Std Dev60.51%

Net Income / Employee (TTM)$-1,019,000

ROE (Last FY)-50.56%

EPS Basic Excl Extra (Annual)$-2.97

Total Debt / Equity (Quarterly)0.01x

EPS Incl Extra (TTM)$-2.97

Receivables Turnover (Annual)152.00x

ROI (TTM)-49.86%

P/S Ratio (TTM)9.09x

Pretax Margin (5Y Avg)-332.49%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$7.67

Price vs S&P 500 (52W)12.91%

Year-to-Date Return18.23%

5-Day Price Return-4.36%

EPS Normalized (Annual)$-2.97

ROA (5Y Avg)-26.23%

Net Profit Margin (Annual)-43.94%

Month-to-Date Return-7.22%

Cash Flow / Share (TTM)$-0.77

EBITD / Share (Annual)$-3.13

Operating Margin (Annual)-59.51%

ROI (5Y Avg)-31.99%

EPS Basic Excl Extra (TTM)$-2.97

P/TBV (Quarterly)3.42x

P/B Ratio (Annual)2.54x

Pretax Margin (TTM)-36.53%

Book Value / Share (Annual)$6.49

Price vs S&P 500 (13W)-9.17%

Beta1.04x

P/FCF (Annual)7.50x

Revenue / Share (TTM)$0.00

ROE (TTM)-50.13%

52-Week Low$12.58

vGradeD

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.69est. -0.74

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.36

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
DNLIDenali Therapeutics Inc. Common Stock	D	—	C	$19.52
AMGNAmgen Inc	C	C	C	$349.58
GILDGilead Sciences Inc	C	B	C	$129.16
ARGXargenx SE American Depositary Shares	D	A	B	$891.32
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$149.23
BIIBBiogen Inc. Common Stock	B	D	B	$195.34
BNTXBioNTech SE American Depositary Share	C	C	D	$88.08
MRNAModerna, Inc. Common Stock	C	B	B	$47.44
NBIXNeurocrine Biosciences Inc	C	B	B	$163.88
EXELExelixis Inc	C	B	B	$52.70
KRYSKrystal Biotech, Inc. Common Stock	D	B	A	$301.00

About

Denali Therapeutics is a biotechnology company developing therapeutics for neurodegenerative diseases, with a lead program targeting LRRK2 inhibition for Parkinson's disease. Its pipeline includes multiple candidates leveraging proprietary delivery technologies, including antibody and enzyme transport vehicles designed to penetrate the blood-brain barrier.